Article
Oncology
A. Bardia, W. A. Messersmith, E. A. Kio, J. D. Berlin, L. Vahdat, G. A. Masters, R. Moroose, A. D. Santin, K. Kalinsky, V Picozzi, J. O'Shaughnessy, J. E. Gray, T. Komiya, J. M. Lang, J. C. Chang, A. Starodub, D. M. Goldenberg, R. M. Sharkey, P. Maliakal, Q. Hong, W. A. Wegener, T. Goswami, A. J. Ocean
Summary: This study summarized the safety and efficacy data of using SG to treat patients with advanced epithelial cancers, identifying common treatment-related adverse events such as nausea, diarrhea, and fatigue. Neutropenia was more frequent in some patients, and efficacy was observed in multiple cancer cohorts.
ANNALS OF ONCOLOGY
(2021)
Article
Oncology
Joan Tymon-Rosario, Elena Bonazzoli, Stefania Bellone, Aranzazu Manzano, Silvia Pelligra, Adele Guglielmi, Barbara Gnutti, Nupur Nagarkatti, Burak Zeybek, Paola Manara, Luca Zammataro, Justin Harold, Dennis Mauricio, Natalia Buza, Pei Hui, Gary Altwerger, Gulden Menderes, Elena Ratner, Mitchell Clark, Vaagn Andikyan, Gloria S. Huang, Dan-Arin Silasi, Masoud Azodi, Peter E. Schwartz, Alessandro D. Santin
Summary: The study evaluated the preclinical activity of DHES0815A against primary USC cell lines and xenografts, finding that DHES0815A is highly selective and toxic to USC tumors overexpressing HER2/neu.
GYNECOLOGIC ONCOLOGY
(2021)
Review
Biotechnology & Applied Microbiology
Mariane S. Fontes, Daniel Vargas Pivato de Almeida, Clarissa Cavalin, Scott T. Tagawa
Summary: Urothelial carcinoma is a common genitourinary malignancy with poor prognosis. Sacituzumab govitecan, an ADC targeting Trop-2, has shown promising efficacy and safety in the treatment of locally advanced and metastatic urothelial cancer. However, not all patients respond to this therapy, highlighting the importance of understanding resistance mechanisms and predictive biomarkers for improved outcomes.
ONCOTARGETS AND THERAPY
(2022)
Article
Pharmacology & Pharmacy
Wensheng Liu, Qiong Du, Zihan Guo, Xuan Ye, Jiyong Liu
Summary: This study investigated SG-related adverse events in real-world settings using the FAERS database, finding significant risks in hepatobiliary disorders and blood lymphatic system disorders and identifying potential emerging safety issues. The results provide important vigilance evidence for clinicians and pharmacists to manage the safety issues of SG.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Biotechnology & Applied Microbiology
Ilana Schlam, Paolo Tarantino, Sara M. Tolaney
Summary: This article summarizes the use of Trop2-targeted ADC SG in the treatment of metastatic breast cancer, discusses its toxicity profile, and provides strategies for managing adverse events.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2023)
Article
Oncology
Vinay Mathew Thomas, Nishita Tripathi, Neeraj Agarwal, Umang Swami
Summary: This review discusses the available data on Sacituzumab govitecan for the treatment of locally advanced or metastatic urothelial cancer, including its mechanism of action, pharmacology, efficacy, and safety.
EXPERT REVIEW OF ANTICANCER THERAPY
(2022)
Review
Oncology
Blair Mcnamara, Levent Mutlu, Michelle Greenman, Justin Harold, Alessandro Santin
Summary: Uterine serous carcinoma (USC) and uterine carcinosarcoma (UCS) are rare and aggressive forms of uterine cancer, with specific mutations that can be targeted by HER2-targeting therapies. This article summarizes the evidence and ongoing clinical trials for these targeted therapies.
Article
Oncology
Anna R. Schreiber, Michelle Andress, Jennifer R. Diamond
Summary: Sacituzumab govitecan has demonstrated promising survival benefits in patients with previously treated mTNBC based on data from the ASCENT trial. Common adverse effects include neutropenia, diarrhea, and nausea, which are manageable with supportive care. In addition to TNBC, Sacituzumab govitecan has shown potential in cancers such as urothelial and lung, and is being studied in HR-positive breast cancers. The therapy is likely to be used in combination with other novel targeted agents as ongoing clinical trials progress.
EXPERT REVIEW OF ANTICANCER THERAPY
(2021)
Article
Pharmacology & Pharmacy
Xingxing Li, Lin Zhang, Sang Hu, Dan Liu, Bin Hu, Jie Ran, Xiaofang Lin, Wei Mao, Jing Hu
Summary: This study explores the adverse events induced by sacituzumab govitecan by analyzing the FDA Adverse Event Reporting System (FAERS) database. It identifies 114 AE signals involving 20 systems, and finds that being male and experiencing colitis, pneumonitis, febrile neutropenia, pyrexia, sepsis, dehydration, and diarrhea are risk factors leading to hospitalization. This study highlights the need for close monitoring of specific adverse reactions when using sacituzumab govitecan.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Oncology
Pierluigi di Mauro, Greta Schivardi, Rebecca Pedersini, Lara Laini, Andrea Esposito, Vito Amoroso, Marta Lagana, Salvatore Grisanti, Deborah Cosentini, Alfredo Berruti
Summary: This article reports a case of a TNBC patient who achieved significant results after receiving sacituzumab govitecan treatment. This treatment can improve the survival rate of early recurrent and BRCA-mutant TNBC patients.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
S. Michaleas, A. Moreno Oliver, J. Mueller-Berghaus, S. B. Sarac, M. E. van der Elst, S. Mueller-Egert, H. Zander, H. Enzmann, F. Pignatti
Summary: Sacituzumab govitecan (SG) is an antineoplastic agent approved as a monotherapy for the treatment of unresectable or metastatic triple-negative breast cancer (mTNBC). SG combines a humanized monoclonal antibody binding to tropoblast cell surface antigen-2 (Trop-2)-expressing cancer cells with a cytotoxic moiety SN-38 (govitecan) that acts as a topoisomerase I inhibitor. A phase III trial showed statistically significant improvements in progression-free survival (PFS) and overall survival (OS) with SG compared to treatment of physician's choice (TPC) in patients with mTNBC. Common side effects of SG include diarrhea, neutropenia, nausea, fatigue, alopecia, anemia, constipation, and vomiting.
Article
Oncology
Yezhe Cheng, Xiaoxi Yuan, Qiang Tian, Xiuying Huang, Yang Chen, Yuzhi Pu, Hu Long, Mingyu Xu, Yafei Ji, Jia Xie, Yuping Tan, Xi Zhao, Hongmei Song
Summary: The study aimed to enhance the intratumoral accumulation of an antibody-drug conjugate (ADC) and reduce its off-target toxicity. SKB264, a novel ADC targeting trophoblast antigen 2 (TROP2), showed promising pharmacologic profiles in vitro and in vivo, with stronger targeting effect and better antitumor activity compared to IMMU-132. These findings suggest the potential therapeutic efficacy of SKB264 for TROP2-positive tumors.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Joan R. Tymon-Rosario, Megan Gorman, Alessandro D. Santin
Summary: Despite a poor prognosis for uterine serous carcinoma (USC), recent advancements in molecular classification and targeted treatments have shown improved survival outcomes. HER2-targeted agents, such as trastuzumab, are important in treating USC, particularly in advanced or recurrent cases. Pembrolizumab and lenvatinib have also shown promising results for recurrent USC. Ongoing trials evaluating various targeted therapies hold promise for effective disease-modifying treatments. Enrollment in clinical trials is highly recommended for personalized cancer care.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2022)
Article
Oncology
Jenny Furlanetto, Frederik Marme, Sibylle Loibl
Summary: Sacituzumab govitecan is a new treatment for metastatic triple-negative breast cancer and hormone receptor-positive breast cancer. It destroys cancer cells by releasing the medication SN-38 and has shown longer overall survival and progression-free survival in clinical trials.
Article
Oncology
Binghe Xu, Fei Ma, Tao Wang, Shusen Wang, Zhongsheng Tong, Wei Li, Xinhong Wu, Xiaojia Wang, Tao Sun, Yueyin Pan, Herui Yao, Xian Wang, Ting Luo, Jin Yang, Xiaohua Zeng, Weihong Zhao, Xiuyu Julie Cong, Jiongjie Chen
Summary: This is the first report on the efficacy and safety of Sacituzumab govitecan in Chinese patients with mTNBC. The study found that Sacituzumab govitecan demonstrated substantial clinical activity in heavily pretreated Chinese patients with mTNBC and had a manageable safety profile.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Dana M. Roque, Eric R. Siegel, Natalia Buza, Stefania Bellone, Dan-Arin Silasi, Gloria S. Huang, Vaagn Andikyan, Mitchell Clark, Masoud Azodi, Peter E. Schwartz, Gautam G. Rao, Jocelyn C. Reader, Pei Hui, Joan R. Tymon-Rosario, Justin Harold, Dennis Mauricio, Burak Zeybek, Gulden Menderes, Gary Altwerger, Elena Ratner, Alessandro D. Santin
Summary: This multi-center study evaluated the activity and safety of ixabepilone plus bevacizumab compared to ixabepilone alone in platinum-resistant/refractory ovarian cancer. The results showed that the combination of ixabepilone and bevacizumab had a higher overall response rate and longer progression-free survival, with good tolerability. Prior receipt of bevacizumab should not limit the use of ixabepilone plus bevacizumab in treatment.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Stefania Bellone, Dana M. Roque, Eric R. Siegel, Natalia Buza, Pei Hui, Elena Bonazzoli, Adele Guglielmi, Luca Zammataro, Nupur Nagarkatti, Samir Zaidi, Jungsoo Lee, Dan-Arin Silasi, Gloria S. Huang, Vaagn Andikyan, Shari Damast, Mitchell Clark, Masoud Azodi, Peter E. Schwartz, Joan R. Tymon-Rosario, Justin A. Harold, Dennis Mauricio, Burak Zeybek, Gulden Menderes, Gary Altwerger, Elena Ratner, Ludmil B. Alexandrov, Akiko Iwasaki, Yong Kong, Eric Song, Weilai Dong, Julia A. Elvin, Jungmin Choi, Alessandro D. Santin
Summary: This study highlights the prognostic significance of Lynch-like cancers versus sporadic MSI-H/dMMR ECs for objective response rate, progression-free survival, and overall survival when treated with pembrolizumab. Sporadic MSI-H ECs exhibit mechanisms of resistance such as defective antigen processing/presentation and deranged induction in interferon responses. Oligoprogression in MSI-H/dMMR patients can be salvaged with surgical resection and/or local treatment and continuation of pembrolizumab off study. Further clinical studies are warranted to evaluate different MSI-H/dMMR EC subtypes treated with ICIs.
Article
Oncology
Marianna Buttarelli, Alessandra Ciucci, Fernando Palluzzi, Giuseppina Raspaglio, Claudia Marchetti, Emanuele Perrone, Angelo Minucci, Luciano Giaco, Anna Fagotti, Giovanni Scambia, Daniela Gallo
Summary: Predicting the response of BRCAwt HGSOC patients to first-line chemotherapy using a gene signature is a challenging yet meaningful task.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Joan R. Tymon-Rosario, Paola Manara, Diego D. Manavella, Stefania Bellone, Tobias Max Philipp Hartwich, Justin Harold, Yang Yang-Hartwich, Margherita Zipponi, Jungmin Choi, Kyungjo Jeong, Levent Mutlu, Kevin Yang, Gary Altwerger, Gulden Menderes, Elena Ratner, Gloria S. Huang, Mitchell Clark, Vaagn Andikyan, Masoud Azodi, Peter E. Schwartz, Ludmil B. Alexandrov, Alessandro D. Santin
Summary: The study found that ovarian and uterine carcinosarcoma with HRD signature were more sensitive to olaparib. The experiments showed that olaparib inhibited the growth of carcinosarcoma cells by blocking the cell cycle and inducing apoptosis. In the xenograft experiment, olaparib significantly suppressed the growth of HRD carcinosarcoma and improved overall survival.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Ghanshyam Yadav, Dana M. Roque, Stefania Bellone, Diego D. Manavella, Tobias M. P. Hartwich, Margherita Zipponi, Justin Harold, Joan Tymon-Rosario, Levent Mutlu, Gary Altwerger, Gulden Menderes, Elena Ratner, Natalia Buza, Pei Hui, Gloria S. Huang, Vaagn Andikyan, Mitchell Clark, Masoud Azodi, Peter E. Schwartz, Ludmil B. Alexandrov, Alessandro D. Santin
Summary: The efficacy of neratinib and olaparib as single agents and in combination for uterine serous carcinoma (USC) was evaluated. Neratinib was more effective than olaparib in suppressing the growth of HER2/neu overexpressing USC cell lines. The combination of olaparib and neratinib showed a stronger inhibition of USC cell lines in vitro and suppressed tumor growth in vivo.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Health Care Sciences & Services
Luka Mihic-Gongora, Paula Jimenez-Fonseca, Raquel Hernandez, Mireia Gil-Raga, Vilma Pacheco-Barcia, Aranzazu Manzano-Fernandez, Susana Hernando-Polo, Monica Antonanzas-Basa, Maria J. Corral, Maria Valero-Arbizu, Caterina Calderon
Summary: This study investigated the sociodemographic factors related to psychological distress, spirituality, and resilience in patients with advanced, unresectable cancer during the Covid-19 pandemic, and examined the mediating role of spirituality. The results showed that spirituality was significantly different according to age and marital status. Psychological distress accounted for 12% of the variance in resilience, while spirituality accounted for an additional 15%. Spirituality acted as a partial mediator in the relationship between psychological distress and resilience in individuals with advanced cancer.
BMC PALLIATIVE CARE
(2022)
Article
Oncology
Ryan D. Chow, Tai Michaels, Stefania Bellone, Tobias M. P. Hartwich, Elena Bonazzoli, Akiko Iwasaki, Eric Song, Alessandro D. Santin
Summary: This study found that patients with mutational MMRd endometrial cancer had higher response rates and longer survival after treatment with the PD-1 inhibitor pembrolizumab compared to those with epigenetic MMRd. However, mutation burden did not correlate with immune checkpoint blockade response. The study also revealed different modes of antitumor immunity between mutational and epigenetic MMRd cancers.
Article
Oncology
Emanuele Perrone, Riccardo Tudisco, Pia Clara Pafundi, Davide Guido, Alessandra Ciucci, Enrica Martinelli, Gian Franco Zannoni, Alessia Piermattei, Saveria Spadola, Giulia Ferrante, Claudia Marchetti, Giovanni Scambia, Anna Fagotti, Daniela Gallo
Summary: This study explored the relationship between hormone receptor status and BRCA1/2 mutation in high-grade serous ovarian carcinoma (HGSOC) patients. The results showed interesting differences in receptor expression patterns and their association with outcomes between BRCA-mutated and BRCA wild-type women. The findings suggest a potential role of estrogen-mediated pathways in BRCA1/2-associated HGSOC tumorigenesis, revealing a possible therapeutic potential for targeting this interaction.
Editorial Material
Pharmacology & Pharmacy
Gloria Shining Huang, Joan Tymon-Rosario, Alessandro D. D. Santin
EXPERT OPINION ON PHARMACOTHERAPY
(2023)
Article
Oncology
Justin Harold, Stefania Bellone, Diego D. Manavella, Levent Mutlu, Blair McNamara, Tobias Max Philipp Hartwich, Margherita Zipponi, Yang Yang-Hartwich, Cem Demirkiran, Miguel Skyler Verzosa, Jungmin Choi, Weilai Dong, Natalia Buza, Pei Hui, Gary Altwerger, Gloria S. Huang, Vaagn Andikyan, Mitchell Clark, Elena Ratner, Masoud Azodi, Peter E. Schwartz, Alessandro D. Santin
Summary: This study investigated the in vivo activity of the novel ATR inhibitor BAY1895344 against uLMS patient-derived xenografts (PDXs) with ATRX mutations. The results demonstrated significant growth inhibition and prolonged overall survival in the tumor models treated with BAY1895344, without significant toxicity.
GYNECOLOGIC ONCOLOGY
(2023)
Review
Oncology
Ilaria Capasso, Angela Santoro, Emanuela Lucci Cordisco, Emanuele Perrone, Francesca Tronconi, Ursula Catena, Gian Franco Zannoni, Giovanni Scambia, Francesco Fanfani, Domenica Lorusso, Simona Duranti
Summary: Lynch syndrome is a genetic condition that increases the risk of various tumors, including endometrial and ovarian cancers. Universal screening is recommended for detecting Lynch syndrome. Surgery, chemoprevention, and immunotherapy are viable options for treatment.
Article
Oncology
Eun Mi Lee, Paula Jimenez-Fonseca, Raquel Hernandez, Patricia Cruz-Castellanos, Ana Fernandez-Montes, Jacobo Rogado, Mireia Gil-Raga, Monica Antonanzas, Helena Lopez-Ceballos, Caterina Calderon
Summary: Financial difficulties have a negative impact on the mental health of cancer patients. This study examined the mediating role of financial difficulties between physical symptoms and depression in patients with advanced cancer. A cross-sectional design was used to collect data from 861 participants in Spain. Results showed that 24% of patients reported high levels of financial difficulties. Physical symptoms were positively associated with financial difficulties and depression, and financial difficulties were also positively associated with depression. Financial difficulties mediated the relationship between physical symptoms and depression, with a standardized regression coefficient of 0.43. It decreased to 0.39 after controlling for financial difficulties. Healthcare professionals should consider providing financial resources and emotional support to help patients cope with the financial burden of cancer treatment and symptoms.
